Alzheimer's disease: treatments in discovery and development
- 28 October 2002
- journal article
- review article
- Published by Springer Nature in Nature Neuroscience
- Vol. 5 (S11) , 1055-1057
- https://doi.org/10.1038/nn940
Abstract
Alzheimer's disease is the single biggest unmet medical need in neurology. Current drugs are safe, but of limited benefit to most patients. This review discusses the scientific basis and current status of promising disease-modifying therapies in the discovery and development stages. I describe the major targets of anti-amyloid therapy and the main focus of disease modification approaches. In addition, two new potential treatment approaches supported by retrospective epidemiology are outlined.Keywords
This publication has 26 references indexed in Scilit:
- aph-1 and pen-2 Are Required for Notch Pathway Signaling, γ-Secretase Cleavage of βAPP, and Presenilin Protein AccumulationDevelopmental Cell, 2002
- γ-Secretase, notch, Aβ and alzheimer's disease: Where do the presenilins fit in?Nature Reviews Neuroscience, 2002
- Transgenic mouse models of Alzheimer's diseaseTrends in Genetics, 2001
- Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generationNature Neuroscience, 2001
- Structure of the Protease Domain of Memapsin 2 (β-Secretase) Complexed with InhibitorScience, 2000
- Purification and cloning of amyloid precursor protein β-secretase from human brainNature, 1999
- β-Secretase Cleavage of Alzheimer's Amyloid Precursor Protein by the Transmembrane Aspartic Protease BACEScience, 1999
- The role of Aβ42 in Alzheimer's diseaseJournal of Physiology-Paris, 1998
- The Seminal Role of β-Amyloid in the Pathogenesis of Alzheimer DiseaseAlzheimer Disease & Associated Disorders, 1992
- Amyloid deposition as the central event in the aetiology of Alzheimer's diseaseTrends in Pharmacological Sciences, 1991